JP2023504547A5 - - Google Patents

Info

Publication number
JP2023504547A5
JP2023504547A5 JP2022533470A JP2022533470A JP2023504547A5 JP 2023504547 A5 JP2023504547 A5 JP 2023504547A5 JP 2022533470 A JP2022533470 A JP 2022533470A JP 2022533470 A JP2022533470 A JP 2022533470A JP 2023504547 A5 JP2023504547 A5 JP 2023504547A5
Authority
JP
Japan
Prior art keywords
composition according
subject
dosage form
unit dosage
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063281 external-priority patent/WO2021113620A1/en
Publication of JP2023504547A publication Critical patent/JP2023504547A/ja
Publication of JP2023504547A5 publication Critical patent/JP2023504547A5/ja
Pending legal-status Critical Current

Links

JP2022533470A 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Pending JP2023504547A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US62/944,282 2019-12-05
US202063074785P 2020-09-04 2020-09-04
US63/074,785 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2023504547A JP2023504547A (ja) 2023-02-03
JP2023504547A5 true JP2023504547A5 (https=) 2023-12-11

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533470A Pending JP2023504547A (ja) 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法

Country Status (8)

Country Link
US (1) US20220296563A1 (https=)
EP (1) EP4069209A4 (https=)
JP (1) JP2023504547A (https=)
CN (1) CN114901267A (https=)
AU (1) AU2020396554A1 (https=)
BR (1) BR112022010672A2 (https=)
CA (1) CA3163342A1 (https=)
WO (1) WO2021113620A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
FR2720936B1 (fr) * 1994-06-08 1997-04-30 Synthelabo Poudres à base de métoclopramide et de paracétamol ou de dérivés d'acide acétylsalicylique.
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
DE19726871C1 (de) * 1997-06-24 1999-03-04 Werner Kreutz Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
PT2056815E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
US8834858B2 (en) * 2010-07-02 2014-09-16 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
CA3102404A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP3801489A4 (en) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Similar Documents

Publication Publication Date Title
CN103338762B (zh) 血糖值上升抑制剂
JP2021528384A5 (https=)
US6207714B1 (en) Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
EP3723511A1 (en) Compositions and methods for weight loss maintenance
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
WO2020009111A1 (ja) 脂肪蓄積抑制用組成物
US20020193430A1 (en) Correcting polymorphic metabolic dysfunction with (-)- hydroxycitric acid
JP2022524962A (ja) 中鎖トリグリセリドの食前投与により食事に由来する食後血糖を低減する方法
US20240130994A1 (en) Ionic liquid formulations for treating diabetes
WO2007049818A1 (ja) 抗脂肪肝、抗肥満及び抗高脂血症用組成物
JPWO2007114499A1 (ja) 抗脂肪蓄積用組成物
WO2022230920A1 (ja) 血中カルニチン増加剤
HK1257401A1 (zh) 用於治疗糖尿病和相关病症的方法和组合物
JP2023504547A5 (https=)
JP2023505233A5 (https=)
WO2018102914A1 (en) Use of medium-chain triglycerides for the management of metabolic conditions
EP2730281B1 (en) Anti-obesity agent comprising high-purity epa
JP2001247457A (ja) 血糖値低下剤
CN112955132A (zh) 用于预防或治疗肥胖或非酒精性脂肪性肝炎的包含氢醌衍生物的药物组合物
CN100594933C (zh) 抗肥胖剂和健康食品
EP1156795A1 (en) Use of succinic acid or salts thereof and method of treating insulin resistance
JPWO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
EP1219297A1 (en) Antiobestic agents
WO2025148866A1 (en) Use of dihydroberberine or its derivatives for regulating glp-1
US20240423941A1 (en) Medium chain dicarboxylic acids for the treatment and prevention of diseases and conditions